FDA clears Angle’s Parsortix breast cancer system

LabPulse.com staff writers
Jul 27, 2022
2022 07 28 17 23 1016 Breast Biopsy Mammotome 400

Angle has announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Parsortix PCI Clinical System for use with metastatic breast cancer (MBC) patients.

The FDA clearance is the first FDA product clearance to harvest cancer cells from a blood sample for subsequent analysis. This offers the prospect of a new era of personalized cancer care, according to the company.

The Parsortix system's ability to harvest cancer cells for analysis from a blood sample has the potential to transform treatment decisions for patients, as it allows for the opportunity for repeat noninvasive biopsies to assess cancer status. The Parsortix system's approach utilizes technology developed, owned, and patent-protected by Angle.

Latest in FDA Clearance
Fda Button Social
Prenosis gets FDA authorization for AI-based sepsis diagnostic tool
April 8, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Fda Sign Dc Social
BioMĂ©rieux gets FDA 510(k) clearance, CLIA waiver approval for panel
March 27, 2024
Artery Heart 3 D Social
Boston Scientific gets FDA approval for drug-coated balloon catheter
March 4, 2024
Related Stories
2021 02 24 22 29 5379 Breast Cancer 20210224225528 20220322220342
Breast Cancer
cfDNA detection may simplify breast cancer monitoring: study
2022 07 27 14 51 5076 Doctor Analysis Clinical Samples 400
510(k)
Siemens Healthineers unveils in vitro diagnostics systems at AACC 2022
2020 08 27 17 11 6347 Infectious Diseases Research 400
Bacterial Infections
DiaSorin nabs FDA clearance for infectious disease blood test
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in FDA Clearance
Prenosis gets FDA authorization for AI-based sepsis diagnostic tool
By LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has granted de novo marketing authorization to artificial intelligence (AI) healthcare firm Prenosis' AI-based ImmunoScore sepsis risk-assessment software.
April 8, 2024
Fda Button Social
Basilea gets FDA approval for antibiotic
By LabPulse.com staff writers
Swiss pharmaceutical manufacturer Basilea has received U.S. Food and Drug Administration (FDA) approval for its antibiotic Zevtera (ceftobiprole) for three different types of infections.
April 4, 2024
Fda Sign Dc Social
BioMĂ©rieux gets FDA 510(k) clearance, CLIA waiver approval for panel
By LabPulse.com staff writers
BioMĂ©rieux's Biofire Spotfire Respiratory/Sore Throat Panel has received dual FDA 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver approval.
March 27, 2024
Fda Sign Dc Social
Boston Scientific gets FDA approval for drug-coated balloon catheter
By LabPulse.com staff writers
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for its Agent drug-coated balloon, a paclitaxel-coated balloon catheter sized to fit within blocked or constricted coronary arteries to treat coronary in-stent restenosis.
March 4, 2024
Artery Heart 3 D Social
FDA grants accelerated approval to Iovance’s melanoma cell therapy
By LabPulse.com staff writers
The FDA granted accelerated approval to Iovance Biotherapeutics’ T-cell therapy treatment for unresectable or metastatic melanoma.
February 21, 2024
Melanoma Social
T2 Biosystems gets FDA nod to expand bacteria panel
By LabPulse.com staff writers
T2 Biosystems announced it received 510(k) clearance to add A. baumannii to its T2Bacteria Panel.
February 12, 2024
Fda Button Social
Why many high-risk IVDs are being reclassified
By LabPulse.com staff writers
The FDA announced that its Center for Devices and Radiological Health (CDRH) will reclassify most in vitro diagnostics (IVDs) that are in the high-risk category to moderate risk to allow their manufacturers an easier path to FDA clearance.
February 1, 2024
Fda Sign Dc Social
Imvaria gets FDA marketing authorization for Fibresolve
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration (FDA) has cleared Imvaria for the use of Fibresolve.
January 16, 2024
Lungs 3 D Research 400
FDA approves test for opioid use disorder risk assessment
By LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has approved a test designed to determine if a patient is at risk of developing opioid use disorder (OUD).
December 21, 2023
Pills Bottle Social
FDA approves Abbott laboratory automation system
By LabPulse.com staff writers
Abbott’s new laboratory automation system has received U.S. Food and Drug Administration (FDA) approval, the company announced in a statement.
December 14, 2023
Fda Button Social
FDA clears BD’s new fingerstick blood collection device
By LabPulse.com staff writers
BD (Beckton, Dickinson and Company) received 510(k) clearances from the U.S. Food and Drug Administration (FDA) for its new sample collection device system that pulls blood from a fingerstick to enable common blood tests without need for a phlebotomist.
December 7, 2023
Fda Sign Dc Social
KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy
By LabPulse.com staff writers
Biotech firm KSQ Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a phase I and II trial of KSQ-001EX, KSQ’s CRISPR-Cas9 engineered tumor-infiltrating lymphocyte program.
November 29, 2023
Crispr Cas9 Gene Editing Social
Page 1 of 7
Next Page